ReviewJournal of cheminformatics2025
Generative artificial intelligence based models optimization towards molecule design enhancement.
Review in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Decoding cancer with artificial intelligence: Transforming research, diagnosis, and therapy with future insights.Translational oncology · 2026Review
- Leveraging Advanced AI Frameworks for Dual PPAR α/γ Agonist Discovery in Alzheimer's Disease.ACS chemical neuroscience · 2026Review
- Smart molecular design of NIR-II organic fluorophores through self-driven iterative evolution, deep learning, and fragment-based assembly.Smart molecules : open access · 2026Article
- From mechanistic modeling to AI-driven design: computational strategies for targeting the γ-secretase complex.Briefings in bioinformatics · 2026Review
- NaviDiv: a web app for monitoring chemical diversity in generative molecular design.Digital discovery · 2026Article
- Artificial intelligence-driven drug discovery: a deep learning paradigm shift in pharmaceutical research and development.Frontiers in pharmacology · 2026Review
- Integrating artificial intelligence across the cancer drug discovery pipeline using a design-test-refine workflow.Frontiers in oncology · 2026Review
- From microfluidics to nanodelivery: artificial intelligence reshapes neuropharmacology research strategies.Frontiers in pharmacology · 2026Review
- AI-driven molecular modeling and design: from property prediction to drug generation.Journal of computer-aided molecular design · 2025Article
- AI-Integrated Micro/Nanorobots for Biomedical Applications: Recent Advances in Design, Fabrication, and Functions.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generative artificial intelligence (GenAI) models have emerged as a transformative tool for addressing the complex challenges of drug discovery, enabling the design of structurally diverse, chemically valid, and functionally relevant molecules. Despite significant advancements, the rapid expansion of GenAI applications still faces challenges related to prediction accuracy, molecular validity, and optimization for drug-like properties. This review provides a comprehensive analysis of recent techniques and strategies aimed at enhancing the performance of GenAI models in molecular design. We explore key generative architectures, including variational autoencoders, generative adversarial networks, and transformer-based models, highlighting their unique contributions to drug discovery. Additionally, we discuss critical advancements such as reinforcement learning, multi-objective optimization, and the integration of domain-specific chemical knowledge, which collectively enhance molecular validity, novelty, and drug-likeness. Also, the review examines persistent challenges, including data quality limitations, model interpretability, and the need for improved objective functions, while offering insights into future research directions. By mapping the evolving landscape of GenAI-driven molecular design and providing strategic guidance for overcoming existing limitations, this review serves as an essential resource for researchers leveraging GenAI in drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.